Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hua Medicine’s Diabetes Drug Shows Efficacy in Phase Ic Trial

publication date: Aug 12, 2015
Hua Medicine of Shanghai reported that its lead program, HMS5552, a novel oral glucokinase activator (GKA) treatment for Type 2 diabetes, produced a surprising 1% HbA1c average reduction in patients' blood glucose levels after only 4 weeks of treatment. The positive data were part of a China Phase Ic trial. Hua said the drug candidate also showed an excellent tolerability and safety profile with low risk of hypoglycemia or gastrointestinal discomfort. Hua has already begun a China Phase II trial of the drug. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital